The evolving epidemiology of invasive meningococcal disease: a two-year prospective, population-based study in children in the area of Athens

Vaccination News Home Page            Scandals            subscribe Vaccination NewsLetter

http://www.elsevier.com/gej-ng/10/19/36/99/25/38/abstract.html

Logo
FEMS Home Elsevier Journal Information Instructions for Authors Search Author Index Keyword Index
 


FEMS Immunology and Medical Microbiology, Vol. 36 (1-2) (2003) pp. 87-94
© 2003 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.
PII: S0928-8244(03)00083-X
 

The evolving epidemiology of invasive meningococcal disease: a two-year prospective, population-based study in children in the area of Athens

Maria N. Tsolia a * matsolia@ath.forthnet.gr , Maria Theodoridou b, Georgina Tzanakaki c, Panayotis Kalabalikis d, Evangelia Urani e, Glykeria Mostrou b, Anastasia Pangalis f, Anthi Zafiropoulou g, Corina Kassiou h, Dimitris A. Kafetzis a, C. Caroline Blackwell c,i, Jenny Kremastinou c and Th. E. Karpathios a

a Second Department of Pediatrics, University of Athens, P. and A. Kyriakou Children's Hospital, 115 27 Athens, Greece
b First Department of Pediatrics, University of Athens, Aghia Sophia Children's Hospital, Athens, Greece
c National Meningococcal Reference Laboratory, NSPH, Athens, Greece
d ICU, Aghia Sophia Children's Hospital, Athens, Greece
e ICU, P. and A. Kyriakou Children's Hospital, Athens, Greece
f Microbiology laboratory, Aghia Sophia Children's Hospital, Athens, Greece
g Microbiology laboratory, P. and A. Kyriakou Children's Hospital, Athens, Greece
h First and Second Department of Pediatrics, Aghia Sophia Children's Hospital, Athens, Greece
i Immunology and Microbiology, University of Newcastle, Newcastle, Australia

Received 22 April 2002; received in revised form 3 February 2003; accepted 5 February 2003

Abstract

In response to an increase in the incidence in invasive meningococcal disease (IMD) due to Neisseria meningitidis, a system of hospital- and laboratory-based surveillance was used in a prospective epidemiological and clinical assessment of IMD in children 0-13 years of age hospitalized in the Athens area between 1 January 1999 and 31 December 2000. The annual incidence of laboratory-confirmed disease was 10.2/100,000. Serogroup B strains were predominant. There was a sharp decrease in serogroup C from 19% of cases in 1999 to 3% in 2000 (P=0.013). Of note was the emergence of serogroup A responsible for 7% of the cases. The overall case fatality rate was 4.5%, but 2.8% for microbiologically confirmed cases. A remarkable decrease in disease severity assessed by admissions to intensive care units was noted during the second study year. Polymerase chain reaction-based methods for detection of meningococcal DNA were the sole positive laboratory test in 45% of the cases and the only test on which serogroup determination was based in 52% of groupable cases. The epidemiological and clinical profile of meningococcal disease appears to be rapidly evolving and close monitoring is required particularly for input into decisions regarding use of meningococcal vaccines.

Keywords: Neisseria meningitidis; Epidemiology; Greece; Serogroup C; Serogroup A; Polymerase chain reaction

*Corresponding author. Tel.: +30 210 7726260; Fax: +30 210 7774383

[Full text] (PDF 214.2 Kb)


 

Copyright ©1996-2003  Federation of European Microbiological Societies. All rights reserved.

Note: Our access control system is due to be updated shortly. You will then need to register and select a username and password to access full text, even if you have not had to do so in the past.
Click here for more information.

PDF files should be viewed and printed using Adobe® Acrobat® Reader version 3.01 or higher. Get Acrobat Reader More information about PDF and Adobe® Acrobat® Reader.


Vaccination News Home Page

 

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.